How Indian diplomacy ended crisis in Maldives

NEW DELHI: It was an "understanding" between India and Maldives that resolved an embarrassing political situation in the island country after former president Mohamed Nasheed took refuge inside the Indian high commission, drawing India into the heart of the ongoing political crisis there.

The resolution, which showcased Indian diplomacy at its most effective, confirmed India's position as the pre-eminent power in the Indian Ocean.

Both countries have denied there was a "deal", and there wasn't. Since the moment Nasheed became a refugee in the mission, India and Maldives and, after a while, even Nasheed himself, were looking for a way to end the agony.

On the Indian side, the initiative was led jointly by NSA Shivshankar Menon and foreign minister Salman Khurshid. Khurshid spoke with his counterpart Abdul Samad Abdulla several times in the past week to soften up the government there to the fact that a face-saving solution had to be found for all concerned.

Menon undertook the more complex job of directing the Indian effort, issuing instructions to the Indian team as well as keeping the larger picture of national interest in view. Foreign secretary Ranjan Mathai worked the phones with his counterpart and other leaders in Male from Washington DC where he was travelling. But it was the low-key actions of Harsh Vardhan Shringla, joint secretary in the ministry of external affairs, that finally won the day in Male.

Shringla and his team met an entire cross-section of the Maldives leadership — defence minister Mohamed Nazim, foreign minister Abdul Samad Abdulla, attorney general Aishath Azima Shakoor, even Abdulla Yamin, leader of the Progressive Party of Maldives (Gayoom's party), as well as acting foreign secretary Abdul Azeez Yoosuf, among others. The mission was two-fold — first to convince them that India had no role to play in the political crisis.

Second, to make sure that the election process in Maldives had the field open for all candidates.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Pistorius' Brother Facing Own Homicide Trial

The attorney for Oscar Pistorius' family said today that the Olympian's brother is facing a culpable homicide charge relating to a 2008 road accident in which a motorcyclist was killed.

Carl Pistorius, who sat behind his younger brother, Oscar, every day at his bail hearing, will now face his own homicide trial for the accident five years ago, which his attorney, Kenny Oldwage, said he "deeply regrets."

Carl Pistorius is charged with culpable homicide, which refers to the unlawful negligent killing of another person. The charges were initially dropped, but were later reinstated, Oldwage said in a statement.

Full Coverage: Oscar Pistorius Case

Pistorius quietly appeared in court on Thursday, one day before his Paralympic gold-medalist brother was released on bail, Oldwage said. His next appearance is scheduled for the end of March.

Liza van Deventer/Foto24/Gallo Images/Getty Images

'Blade Runner' Murder Charges: Oscar Pistorius Out on Bail Watch Video

Oscar Pistorius Granted Bail in Murder Case Watch Video

It was the latest twist in a case that has drawn international attention, after 26-year-old Oscar Pistorius, a double amputee who ran in both the 2012 Olympic and Paralympic games, was charged with the premeditated murder of his model girlfriend, Reeva Steenkamp.

On Saturday, Carl Pistorius' Twitter handle was hacked, according to a family spokeswoman, prompting the Pistorius family to cancel their social media accounts.

Steenkamp's parents speak about the Valentine's Day shooting that ended their daughter's life in a sit-down interview on South African television tonight.

On Saturday, the model's father, Barry Steenkamp, told the Afrikaans-language Beeld newspaper that Pistorius will have to "live with his conscience" and will "suffer" if his story that he shot Steenkamp because he believed she was an intruder is false.

RELATED: Oscar Pistorius Case: Key Elements to the Murder Investigation

After a four-day long bail hearing, Pistorius was granted bail Friday by a South African magistrate.

The court set bail at about $113,000 (1 million rand) and June 4 as the date for Pistorius' next court appearance.

Pistoriuis is believed to be staying at his uncle's house as he awaits trial. As part of his bail conditions, Pistorius must give up all his guns, he cannot drink alcohol or return to the home where the shooting occurred, and he must check in with a police department twice a week.

Read More..

Ecuador president vows to push large-scale mining

QUITO: Ecuador's re-elected President Rafael Correa said Saturday he will push large-scale mining projects during his next four years in office, despite opposition from some indigenous groups.

"The Ecuadoran people have voted to responsibly take advantage of non-renewable resources," said in a weekly address on his administration's activities.

Correa, a socialist, said his goal was to use the country's mining and oil wealth to eliminate poverty and said he was committed to "the Amazonian people and all the areas where there is mining or oil."

A year ago, Correa's government signed a contract with the Chinese company Ecuacorriente to mine copper in the Amazon basin province of Zamora-Chinchipe, in a major move to open the country to large-scale mining.

The country's largest indigenous organisation opposed the deal, however, and with the backing of opposition groups led a two-week-long protest march from the Amazon to Quito.

But Correa, who has been in power since 2007, won re-election last week in a landslide, with 56.77 per cent of the vote, and he used his speech Saturday to criticise opponents of big mining.

"To hurt the government, they are hurting the country, the poor, that Amazonian region," Correa said, adding that "we are not with the multinationals, we are with the poor."

"We cannot be beggars sitting in front of a bag of gold," he said.

- AFP/jc

Read More..

Plaint against Baba Ramdev for slamming Gandhis

BELGAUM: A complaint has been registered against yoga guru Baba Ramdev in the fourth JMF Court for allegedly making derogatory statements against AICC president Sonia Gandhi and vice-president Rahul Gandhi.

Former KPCC member Shankar Munavalli filed the case. In a complaint, he alleged that Baba Ramdev, during his visit to Hubli on February 20, said that corruption had increased in the country because "AICC president Sonia Gandhi and his son Rahul were exporting money to Italy".

He also said that both should be expelled from the country, if the country has to become free from corruption. Munavalli claimed that Ramdev deliberately attempted to defame the image of Sonia and Rahul Gandhi without any evidence.

Besides, no complaint had been filed in any court on them as alleged by Ramdev. Munavalli urged action against the yoga guru, saying that his statement hurt the sentiments of Congress party workers.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Fiery Last-Lap Daytona Crash Injures 15 Fans

A fiery last-lap crash at the Daytona International Speedway injured a number of spectators today, who were seen being carried away from the stands on stretchers.

Fifteen spectators were taken to the hospital, according to ESPN, with one on the way to surgery with head trauma.

The 12-car crash happened moments before the end of the Nationwide race, and on the eve of the Daytona 500, one of NASCAR's biggest events.

The crash was apparently triggered when driver Regan Smith's car, which was being tailed by Brad Keselowski on his back bumper, spun to the right and shot up the track. Smith had been in the lead and said after the crash he had been trying to throw a "block."

Rookie Kyle Larson's car slammed into the wall that separates the track from the grandstands, causing his No. 32 car to go airborne and erupt in flames.

When a haze of smoke cleared and Larson's car came to a stop, he jumped out uninjured.

His engine and one of his wheels were sitting in a walkway of the grandstand.

"I was getting pushed from behind," Larson told ESPN. "Before I could react, it was too late."

Driver Michael Annett was taken to the hospital after he slammed head-on into a barrier during the chaos. NASCAR officials told ESPN the driver was awake and alert.

Tony Stewart pulled out the win, but in victory lane, what would have been a celebratory mood was tempered by concern for the injured fans.

"We've always known this is a dangerous sport," Stewart said. 'But it's hard when the fans get caught up in it."

Read More..

Rockets hit Aleppo, killing at least 29: monitor

BEIRUT (Reuters) - Rockets struck eastern districts of Aleppo, Syria's biggest city, on Friday, killing at least 29 people and trapping a family of 10 in the ruins of their home, activists in the city said.

"There are families buried under the rubble," said an activist called Baraa al-Youssef, speaking by Skype after visiting the scene in his Ard al-Hamra neighborhood.

"Nothing can describe it, it's a horrible sight."

Video footage posted by several activists showed a burning building and people carrying the wounded to cars to be ferried to hospital. It was hard to gauge the scale of the damage in the night-time footage but rubble was clearly visible on the ground.

Rami Abdulrahman of the British-based Syrian Observatory for Human Rights said three explosions shook Aleppo and reported at least 29 people had been killed. Another 150 were wounded, he said, and the final death toll was likely to be higher.

Youssef said 30 houses were destroyed by a single rocket.

On Tuesday activists said at least 20 people were killed when a large missile of the same type as Russian-made Scuds hit the rebel-held district of Jabal Badro.

(Reporting by Mariam Karouny and Dominic Evans; Editing by Stephen Powell)

Read More..

Catholic priests should be able to marry: British cardinal

LONDON: Roman Catholic priests should be able to marry and have children, Britain's most senior cardinal said on Friday.

Cardinal Keith O'Brien, who will be part of the conclave tasked with choosing a new pope to replace Benedict XVI, said the church's requirement for priests to be celibate was not of "divine origin" and should be reconsidered.

"Many priests have found it very difficult to cope with celibacy as they lived out their priesthood, and felt the need of a companion, of a woman, to whom they could get married and raise a family of their own," the 74-year-old told the BBC.

"The celibacy of the clergy, whether priests should marry -- Jesus didn't say that.

"There was a time when priests got married, and of course we know at the present time in some branches of the church -- in some branches of the Catholic church -- priests can get married," he added.

"So that is obviously not of divine origin and it could get discussed again."

O'Brien will have a say in who succeeds Benedict after he stands down on February 28.

He said he had not yet decided who should take over leadership of the world's 1.2 billion Catholics, but suggested it could be time for a younger pontiff, possibly from the developing world.

"I would be open to a pope from anywhere if I thought it was the right man, whether it was Europe or Asia or Africa or wherever," he added.

Benedict stunned the world last week by becoming the first pope in more than 700 years to resign voluntarily.

No clear favourite has emerged, although the 85-year-old's announcement that he lacked the strength to lead the church indicates the need for a younger pope.

- AFP/jc

Read More..

Laptops to be Samajwadi Party's anniversary gift to students

LUCKNOW: UP chief minister AkhileshYadav is set to mark his first year in power by distributing free laptops to students who passed their intermediate examination last year during the anniversary week celebrations of his government from March 10 to 15. Free laptops were promised by Akhilesh as a poll sop for the youth.

In the first phase, 10,000 laptops will be distributed in Lucknow and Mainpuri districts to students from government and government-aided schools. Set to cost the state government a total of Rs 2,800 crore, laptops will be embossed with tamper-proof stickers of Akhilesh and SP chief Mulayam Singh Yadav.

It's not laptop alone that the students will get as 'gift'. The machines will be loaded with an open source operating system (Ubuntu) apart from Windows 7 Home Basic. The systems will also come pre-loaded with MS Office software, a specially designed computer literacy programme for first-time users, spreadsheets, multimedia and cloud computing among other things. A special software, designed by the British Council, will have 'How to Learn English', along with 'Hindi to English' and 'English to Hindi' dictionaries. The students will also have access to a photo gallery, movie maker software, photosynth and an editing software.

In another student-friendly initiative, the laptops will be pre-loaded with sample papers of engineering and medical entrance test papers of AIEEE, IIT-JEE, AIIMS, BITS, NIFT, PMT and CLAT. The laptops will come with webcam, blue tooth, wi-fi compatibility, DVD writer and a media reader. Users will have three language options- Hindi, English and Urdu.

Over 15 lakh units are to be distributed over the next seven months. A call centre will be set up in Lucknow with service centres in every district to cater to the beneficiaries. "The service centres will be made operational before the distribution begins," a senior UPEC official said.

Read More..